{"id":"https://openalex.org/W2440918355","doi":null,"title":"Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism?","display_name":"Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism?","publication_year":2004,"publication_date":"2004-04-01","ids":{"openalex":"https://openalex.org/W2440918355","mag":"2440918355","pmid":"https://pubmed.ncbi.nlm.nih.gov/15057640"},"language":"en","primary_location":{"id":"pmid:15057640","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15057640","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100914621","display_name":"J\u00f3zsef Nagy","orcid":"https://orcid.org/0000-0002-0729-0683","observed_orcids":["https://orcid.org/0000-0002-0729-0683"]},"institutions":[{"id":"https://openalex.org/I2808169635","display_name":"Gedeon Richter (Hungary)","ror":"https://ror.org/0033rtn64","country_code":"HU","type":"company","lineage":["https://openalex.org/I2808169635"]}],"countries":["HU"],"is_corresponding":true,"raw_author_name":"Jozsef Nagy","raw_affiliation_strings":["Gedeon Richter Ltd, Pharmacological and Drug Safety Research, PO Box 27, Budapest 10, H-1475 Hungary. jozsef.nagy@richter.hu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gedeon Richter Ltd, Pharmacological and Drug Safety Research, PO Box 27, Budapest 10, H-1475 Hungary. jozsef.nagy@richter.hu","institution_ids":["https://openalex.org/I2808169635"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5100914621"],"corresponding_institution_ids":["https://openalex.org/I2808169635"],"apc_list":null,"apc_paid":null,"fwci":1.5199,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.78236385,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"7","issue":"4","first_page":"339","last_page":"50"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.13420000672340393,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.07739999890327454,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.9879999756813049},{"id":"https://openalex.org/keywords/alcoholism","display_name":"alcoholism","score":0.9459999799728394},{"id":"https://openalex.org/keywords/alcohol-withdrawal-syndrome","display_name":"alcohol withdrawal","score":0.7570000290870667},{"id":"https://openalex.org/keywords/memantine","display_name":"memantine","score":0.6570000052452087},{"id":"https://openalex.org/keywords/glycine-site-antagonists","display_name":"glycine site antagonists","score":0.8429999947547913},{"id":"https://openalex.org/keywords/uncompetitive-antagonists","display_name":"uncompetitive antagonists","score":0.7540000081062317},{"id":"https://openalex.org/keywords/ethanol-tolerance","display_name":"ethanol tolerance","score":0.9300000071525574},{"id":"https://openalex.org/keywords/glutamate-receptors","display_name":"glutamate receptors","score":0.6340000033378601},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.6499999761581421}],"concepts":[{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.8578383922576904},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6720435619354248},{"id":"https://openalex.org/C2779484449","wikidata":"https://www.wikidata.org/wiki/Q412189","display_name":"Memantine","level":4,"score":0.66234290599823},{"id":"https://openalex.org/C115955781","wikidata":"https://www.wikidata.org/wiki/Q6063798","display_name":"Ionotropic effect","level":4,"score":0.5903791189193726},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.48817211389541626},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.44242405891418457},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.38824671506881714},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.370668888092041},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35167497396469116},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3320091664791107},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.27795371413230896},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15442341566085815},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.09904348850250244}],"mesh":[{"descriptor_ui":"D000437","descriptor_name":"Alcoholism","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000437","descriptor_name":"Alcoholism","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:15057640","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15057640","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"},{"id":"mag:2440918355","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15057640","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2054196242","https://openalex.org/W2099210712","https://openalex.org/W1995334423","https://openalex.org/W1964151230","https://openalex.org/W2144724143","https://openalex.org/W2017341242","https://openalex.org/W2051810836","https://openalex.org/W1495702170","https://openalex.org/W1978423412","https://openalex.org/W7095562123"],"abstract_inverted_index":{"Long-term":[0],"alcohol":[1,8,112],"exposure":[2,52],"leads":[3],"to":[4,64,179,199],"the":[5,24,66,92,101,191,200],"development":[6,67],"of":[7,28,37,57,68,80,85,94,111],"dependence,":[9],"which":[10],"is":[11,32],"possibly":[12],"induced":[13],"by":[14],"changes":[15,61],"in":[16,166,173,181],"specific":[17],"neurotransmitter":[18],"functions.":[19,59],"Accumulating":[20],"evidence":[21],"suggests":[22],"that":[23],"N-methyl-D-aspartate":[25],"(NMDA)":[26],"type":[27],"ionotropic":[29],"glutamate":[30],"receptor":[31],"a":[33,54,196],"particularly":[34],"important":[35],"site":[36,133],"action":[38],"for":[39,91,204],"ethanol.":[40],"Ethanol":[41],"potently":[42],"and":[43,49,71,77,108,124,134,160,184],"selectively":[44],"inhibits":[45],"NMDA":[46,137,188],"receptors":[47],"(NMDARs)":[48],"prolonged":[50],"ethanol":[51,69],"produces":[53],"compensatory":[55],"'upregulation'":[56],"NMDAR":[58,96],"These":[60],"are":[62,176],"believed":[63],"underlie":[65],"tolerance":[70],"dependence":[72],"as":[73,75],"well":[74],"acute":[76],"delayed":[78],"signs":[79],"withdrawal.":[81,113],"Therefore,":[82],"negative":[83],"modulators":[84],"NMDARs":[86],"may":[87,194],"be":[88],"useful":[89],"agents":[90],"pharmacotherapy":[93],"alcoholism.":[95,206],"antagonists":[97,138],"attenuate":[98],"not":[99],"only":[100],"physical":[102],"symptoms":[103],"but":[104],"also":[105],"some":[106],"affective":[107],"motivational":[109],"components":[110],"Encouraging":[114],"experimental":[115],"results":[116],"have":[117,163],"been":[118],"obtained":[119],"with":[120],"novel":[121,187],"uncompetitive":[122],"(memantine":[123],"neramexane":[125],"(Merz":[126],"&":[127],"Co":[128,153],"GmbH/Forest":[129],"Laboratories":[130],"Inc)),":[131],"glycine":[132],"NR2B":[135,142],"subunit-selective":[136],"(SSNAs).":[139],"Recently":[140],"emerged":[141],"SSNAs":[143],"(CP-101606":[144],"(Pfizer":[145,148],"Inc),":[146],"Co-101244":[147],"Inc/Purdue":[149],"Neuroscience":[150,157],"Corp/Senju":[151],"Pharmaceutical":[152],"Ltd),":[154],"CI-1041":[155],"(Purdue":[156],"Corp/Pfizer":[158],"Inc)":[159],"indole-2-carboxamide":[161],"derivatives)":[162],"demonstrated":[164],"excellent":[165],"vitro":[167,182],"potency":[168],"against":[169],"withdrawal-induced":[170],"cytotoxicity.":[171],"Although":[172],"vivo":[174],"data":[175],"few,":[177],"according":[178],"their":[180],"efficacy":[183],"good":[185],"tolerability,":[186],"antagonists,":[189,193],"especially":[190],"NR2B-selective":[192],"offer":[195],"preferable":[197],"alternative":[198],"presently":[201],"available":[202],"pharmacotherapies":[203],"treating":[205]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}